ArticleFrontiers in cell and developmental biology2025
Enhanced tenogenic potential of tendon-derived mesenchymal stem cells: transcriptomic profiling and
Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Integrating Single-Cell Sequencing and Proteomics to Unravel Stem Cell Heterogeneity: Implications for Precision Regenerative Medicine.Stem cell reviews and reports · 2026Review
- Transcriptomic and functional comparison of adipose-and bone marrow-derived mesenchymal stem cells for tendon regeneration.Stem cell research & therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tendon injuries represent a significant clinical challenge in the treatment of musculoskeletal disorders due to their restricted intrinsic regenerative capacity and propensity for scar tissue formation. Tendon-derived mesenchymal stem cells (TD-MSCs) are considered a promising therapeutic approach because of their ability to differentiate into tenocytes, modulate inflammation, and secrete trophic factors that facilitate tendon regeneration. However, the molecular mechanisms underlying their effects and therapeutic advantages over other MSC sources remain unclear. This study aimed to elucidate the molecular basis of the therapeutic potential of TD-MSCs through a comprehensive transcriptomic comparison with bone marrow-derived MSCs (BM-MSCs) and evaluate their tenogenic differentiation capacity and regenerative efficacy. We isolated and characterized TD-MSCs and BM-MSCs using flow cytometry, tri-lineage differentiation assays, and proliferation assays (CCK-8) and examined their transcriptomic profiles via RNA sequencing. Subsequently, the tenogenic differentiation potential of TD-MSCs was evaluated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.